

1 **ACUTE VOLUME EXPANSION ATTENUATES HYPERTHERMIA-INDUCED REDUCTIONS IN**  
2 **CEREBRAL PERFUSION DURING SIMULATED HEMORRHAGE**

3  
4 Zachary J. Schlader<sup>1</sup>, Thomas Seifert<sup>2</sup>, Thad E. Wilson<sup>3</sup>, Morten Bundgaard-Nielsen<sup>2</sup>, Niels H.  
5 Secher<sup>2,4</sup>, and Craig G. Crandall<sup>1</sup>

6  
7 <sup>1</sup> Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital of Dallas and  
8 the Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX,  
9 USA

10 <sup>2</sup> Department of Anesthesiology, Rigshospitalet, University of Copenhagen, Denmark

11 <sup>3</sup> Ohio Musculoskeletal and Neurological Institute, Ohio University, and Departments of Biomedical  
12 Sciences and Speciality Medicine, Ohio University Heritage College of Osteopathic Medicine, Athens,  
13 OH, USA

14 <sup>4</sup> Copenhagen Muscle Research Center, Rigshospitalet, University of Copenhagen, Denmark

15  
16  
17 **Corresponding Author:**

18 Craig G. Crandall, PhD  
19 Institute for Exercise and Environmental Medicine  
20 Texas Health Presbyterian Hospital of Dallas  
21 7232 Greenville Ave  
22 Dallas, TX, 75231, USA  
23 Email: CraigCrandall@texashealth.org  
24 Phone: 214-345-4623

25  
26  
27 **Running Head:** Cerebral Perfusion and Volume Expansion during Hyperthermia

28  
29 **Word Count:** 2827

36 **ABSTRACT**

37           Hyperthermia reduces the capacity to withstand a simulated hemorrhagic challenge, but volume  
38 loading preserves this capacity. This study tested the hypotheses that acute volume expansion during  
39 hyperthermia increases cerebral perfusion and attenuates reductions in cerebral perfusion during a  
40 simulated hemorrhagic challenge induced by lower body negative pressure (LBNP). Eight healthy  
41 young male subjects underwent a supine baseline period (pre-LBNP), followed by 15 and 30 mmHg  
42 LBNP while normothermic, hyperthermic (increased pulmonary artery blood temperature  $\sim 1.1^{\circ}\text{C}$ ), and  
43 following acute volume infusion while hyperthermic. Primary dependent variables were: mean middle  
44 cerebral artery blood velocity ( $\text{MCAV}_{\text{mean}}$ ) - serving as an index of cerebral perfusion, mean arterial  
45 pressure (MAP), and cardiac output (thermodilution). During baseline, hyperthermia reduced  $\text{MCAV}_{\text{mean}}$   
46 ( $P=0.001$ ) by  $12 \pm 9\%$  relative to normothermia. Volume infusion while hyperthermic increased cardiac  
47 output by  $2.8 \pm 1.4$  L/min ( $P<0.001$ ), but did not alter  $\text{MCAV}_{\text{mean}}$  ( $P=0.99$ ) or MAP ( $P=0.39$ ), when  
48 compared to hyperthermia alone. Relative to hyperthermia, at 30 mmHg LBNP acute volume infusion  
49 attenuated reductions ( $P<0.001$ ) in cardiac output (by  $2.5 \pm 0.9$  L/min;  $P<0.001$ ), MAP (by  $5 \pm 6$  mmHg;  
50  $P=0.004$ ), and  $\text{MCAV}_{\text{mean}}$  (by  $12 \pm 13\%$ ;  $P=0.002$ ). These data indicate that acute volume expansion  
51 does not reverse hyperthermia-induced reductions in cerebral perfusion pre-LBNP, but that it does  
52 attenuate reductions in cerebral perfusion during simulated hemorrhage in hyperthermic humans.

53

54 Abstract word count: 216

55

56 **Keywords:** Lower body negative pressure; heat stress; brain blood flow; volume infusion

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71 **INTRODUCTION**

72 In humans, the ability to maintain arterial pressure, and ultimately cerebral perfusion, during an  
73 orthostatic (e.g., by standing up or upright tilt) or a simulated hemorrhagic challenge (e.g., by lower  
74 body negative pressure; LBNP (4)) is compromised during hyperthermia (17, 19, 30). This  
75 hyperthermia-induced impairment involves numerous mechanisms including, insufficient increases in  
76 peripheral resistance (8, 14, 25), decreases in ventricular filling pressures (10, 32) - which occur  
77 subsequent to reductions in the central blood volume (9, 10) - impaired arterial baroreflex control of  
78 blood pressure (5), and reductions in cerebral perfusion (2, 21, 30).

79 Various countermeasures are effective in maintaining arterial pressure and cerebral perfusion  
80 during a simulated hemorrhagic challenge in heat stressed individuals, such as rapid skin cooling (31)  
81 and acute plasma volume expansion (17). The mechanism(s) by which acute volume expansion  
82 preserves the capability to maintain cardiovascular integrity during hyperthermia remains unknown.  
83 Volume loading may attenuate the LBNP-induced reduction in stroke volume and cardiac output such  
84 that arterial pressure and therefore, presumably, cerebral perfusion is preserved (3, 10). Alternatively,  
85 acute volume expansion in heat stressed individuals may, independent of changes in arterial pressure,  
86 augment cerebral perfusion secondary to an increase in cardiac output, and subsequent arterial  
87 baroreflex mediated changes in cerebral vascular tone (22, 23), as shown in normothermic individuals  
88 (24). However, the effect of acute volume loading on cerebral perfusion in heat stressed individuals,  
89 either at rest or during a subsequent simulated hemorrhage, remains unknown. Therefore, the purpose  
90 of this study was to test the hypotheses that acute plasma volume expansion while hyperthermic will: 1)  
91 reverse hyperthermia-induced reductions in cerebral perfusion, and 2) attenuate reductions in cerebral  
92 perfusion during a simulated hemorrhagic challenge (i.e., LBNP). The results were considered to  
93 illuminate the mechanisms by which acute volume infusion preserves the capacity to withstand a  
94 subsequent hemorrhagic challenge during hyperthermia, which is of importance for the treatment of  
95 hyperthermic, hemorrhagic individuals.

96

97 **METHODS**

98 Eight healthy male volunteers participated in this study. The subject characteristics were (mean  
99  $\pm$  SD) - Age:  $29 \pm 5$  y; Height:  $180 \pm 5$  cm; Weight:  $75 \pm 4$  kg; Body surface area:  $1.5 \pm 0.1$  m<sup>2</sup>. All  
100 subjects were non-smokers, not taking medications and were free of any known cardiovascular,  
101 metabolic, or neurological diseases. Each subject was fully informed of the experimental procedures  
102 and possible risks before giving informed written consent. This protocol was approved by the Ethics  
103 Committee of Copenhagen (H-KF-090/04) and was registered with the Danish data protection agency  
104 and ClinicalTrials.gov under the national library of medicine (NCT00714766). All procedures  
105 conformed to the standards set by the Declaration of Helsinki. Subjects arrived at the laboratory  
106 euhydrated (having ingested  $\sim 1.8$  L of fluid during the prior 24 h) and having refrained from strenuous  
107 exercise, alcohol and caffeine for a period of 24 h. These data were collected concurrently with those  
108 presented in a published manuscript, which tested a unique research hypothesis (3).

109

110 *Instrumentation and measurements*

111 Mean skin temperature was measured from the weighted average of six thermocouples  
112 attached to the skin (27). Body temperature was controlled via a water-perfused tube lined suit (Med-  
113 Eng, Ottawa, ON, Canada), that covered the entire body except the head, hands, one forearm, and the  
114 feet. Heart rate was continually recorded from a five lead electrocardiogram. Mean arterial pressure  
115 (MAP) was measured via a catheter placed in the brachial artery of the non-dominant arm. Pulmonary  
116 artery blood temperature was measured via a flow-directed pulmonary arterial catheter (93A-831H-  
117 7.5F, Baxter Healthcare Corporation, Irvine, CA, USA) introduced through the basilica vein of the left  
118 arm and advanced to the pulmonary artery. Central venous pressure (CVP) was measured via an  
119 alternate port on the pulmonary arterial catheter. Vascular pressures were referenced to atmospheric  
120 pressure via uniflow pressure transducers (Baxter Healthcare Corporation) that were zeroed 5 cm  
121 below the sternal notch and connected to a pressure-monitoring system (Dialogue 2000, ICB-Danica,  
122 Copenhagen, Denmark). All catheters were flushed with isotonic saline at 3 ml/h. Arterial blood  
123 samples were analyzed for changes in arterial carbon dioxide tension ( $P_a\text{CO}_2$ ), hemoglobin, and thus  
124 hematocrit (Radiometer ABL700, Brønshøj, Denmark) and corrected to pulmonary artery blood  
125 temperature. Cardiac output was measured in triplicate via the thermodilution method (15). Mean  
126 middle cerebral artery blood velocity ( $\text{MCAV}_{\text{mean}}$ ) served as an index of cerebral perfusion and was  
127 measured by adjusting a 2 MHz Doppler probe (Multidop X, DWL, Sippligen, Germany) over the  
128 temporal window (1, 29).

129

130

131

132 *Experimental protocol*

133 Following instrumentation, subjects rested quietly in the supine position while normothermic  
134 water (34°C) perfused the suit. After normothermic baseline data collection, LBNP commenced at 15  
135 mmHg, which was immediately followed by 30 mmHg. 30 mmHg LBNP was the highest level applied  
136 as it was expected that all subjects could tolerate this LBNP during hyperthermia for a period sufficient  
137 to obtain the desired data prior to symptoms of syncope. The duration of each LBNP stage for all  
138 thermal conditions was ~15 min, which was required to obtain the data reported in the companion  
139 paper (3). Following normothermic LBNP, the subjects underwent whole-body passive heat stress by  
140 perfusing 46-48°C water through the suit. This heat stress continued until pulmonary artery blood  
141 temperature increased ~1.0°C (typically after 30-45 min), after which the water temperature was slightly  
142 reduced to attenuate further increases in body temperature during the ensuing data collection periods.  
143 The subjects were not allowed to drink at any time during the experimental procedures. Hyperthermic  
144 baseline data were then obtained, which was followed by 15 and 30 mmHg LBNP. Following a brief  
145 recovery after the cessation of LBNP and while remaining heat stressed, 500 ml of ~38°C colloid  
146 solution (HES 130/0.4, Voluven, Fresenius Kabi, Sweden) followed by warm saline was rapidly infused.  
147 The total infused volume was ~12 ml/kg and typically administered in less than 10 min. Baseline data  
148 were collected after the completion of the infusion, which was then followed by 15 and 30 mmHg LBNP.

149

150 *Data analysis*

151 Thermal, hemodynamic, and pressure data were sampled at 50 Hz via a data acquisition  
152 system (Biopac System, Santa Barbara, CA, USA). Data were reduced into 60 s averages during the  
153 baseline periods and following 5 min of each stage of LBNP. Stroke volume was calculated from  
154 cardiac output and heart rate, while systemic vascular resistance (SVR) was calculated as (MAP –  
155 CVP) divided by cardiac output. An index of cerebral vascular resistance (CVR) was calculated as the  
156 quotient of MAP and  $MCAv_{mean}$ . Percentage changes in plasma volume, occurring as a result of the  
157 volume infusion, were estimated from changes in hematocrit and hemoglobin (12). Data during LBNP  
158 are presented as absolute values and as a change ( $\Delta$ ) from pre-LBNP baseline for each respective  
159 condition.

160

161 *Statistical analysis*

162 Data at baseline for normothermia, hyperthermia, hyperthermia + infusion were analyzed using  
163 one-way repeated measures analysis of variance (ANOVA) (*hypothesis one*), while data during LBNP  
164 during the hyperthermia and hyperthermia + infusion conditions were analyzed using a two-way  
165 repeated measures ANOVA (2 x 3; condition x LBNP) (*hypothesis two*). Data during the normothermic  
166 condition were not included in the analysis for *hypothesis two* given that the inclusion of this data was

167 not necessary to test this hypothesis. Where appropriate, *post hoc*, pair-wise, comparisons were made  
168 incorporating a Bonferroni adjustment. Data were analyzed using SigmaPlot (v.12, Systat Software  
169 Inc., Chicago, IL, USA) with *a priori* statistical significance set at  $P \leq 0.05$ . All data are reported as mean  
170  $\pm$  SD.

171

172 **RESULTS**

173 *Normothermia, hyperthermia, and hyperthermia + volume infusion baselines (hypothesis one)*

174 Thermal and hemodynamic variables during normothermia, hyperthermia, and following the  
175 volume infusion baseline (pre-LBNP) periods are presented in Table 1. Relative to normothermia,  
176 hyperthermia was characterized by  $\sim 1.1$  and  $\sim 2.8^\circ\text{C}$  increases ( $P < 0.001$ ) in pulmonary artery blood  
177 and mean skin temperatures, respectively, which were maintained ( $P = 0.084$ ) during the infusion. The  
178 volume infusion increased plasma volume by  $18 \pm 5\%$ , and augmented ( $P < 0.001$ ) cardiac output, but  
179 did not affect ( $P = 0.999$ ) MAP. Notably,  $P_a\text{CO}_2$  was well maintained ( $P = 0.351$ ) throughout these  
180 baseline periods.  $\text{MCAV}_{\text{mean}}$  and CVR at baseline are presented in Figure 1. Relative to normothermia,  
181  $\text{MCAV}_{\text{mean}}$  was reduced ( $P = 0.001$ ) by  $12 \pm 9\%$  during hyperthermia and was unaffected ( $P = 0.394$ ) by  
182 volume infusion. CVR was similar ( $P = 0.471$ ) throughout all baseline periods.

183

184 *Lower body negative pressure (hypothesis two)*

185 Pulmonary artery temperature was  $\sim 0.2^\circ\text{C}$  higher ( $P = 0.006$ ) throughout LBNP following the  
186 volume infusion ( $38.0 \pm 0.3^\circ\text{C}$ ), relative to during hyperthermia alone ( $37.8 \pm 0.4^\circ\text{C}$ ).  $\text{MCAV}_{\text{mean}}$  and  
187 CVR during LBNP are presented in Figure 2. CVR remained constant ( $P = 0.281$ ) as LBNP progressed,  
188 while  $\text{MCAV}_{\text{mean}}$  decreased ( $P < 0.001$ ) in both conditions. However, relative to hyperthermia, volume  
189 infusion attenuated the reduction in  $\text{MCAV}_{\text{mean}}$  during 15 ( $P = 0.049$ ) and 30 ( $P = 0.002$ ) mmHg LBNP.  
190 Hemodynamic variables during LBNP are presented in Figure 3. Cardiac output, stroke volume, MAP,  
191 and CVP all decreased ( $P < 0.001$ ) as LBNP progressed, while SVR increased ( $P < 0.001$ ). At both  
192 stages of LBNP, volume infusion augmented ( $P \leq 0.001$ ) cardiac output and stroke volume, while it  
193 attenuated ( $P = 0.004$ ) the reduction in MAP at 30 mmHg LBNP. During LBNP,  $P_a\text{CO}_2$  was similar  
194 ( $P = 0.559$ ) between hyperthermia ( $33 \pm 5$  mmHg) and volume infusion ( $35 \pm 5$  mmHg) conditions.

195

196

197 **DISCUSSION**

198 The purpose of this study was to test the hypotheses that acute plasma volume expansion  
199 during hyperthermia elevates cerebral perfusion at rest and attenuates reductions in cerebral perfusion  
200 during a subsequent simulated hemorrhagic challenge. The novel findings of this study are that acute  
201 volume expansion: a) does not reverse hyperthermia-induced reductions in cerebral perfusion at rest,  
202 but that b) it attenuates reductions in cerebral perfusion during a subsequent simulated hemorrhage  
203 while hyperthermic. That is, an increase in pulmonary artery blood temperature of  $\sim 1.1^{\circ}\text{C}$  (Table 1)  
204 reduced  $\text{MCAV}_{\text{mean}}$  by  $\sim 12\%$  (Fig. 1), but acute volume infusion sufficient to increase cardiac output by  
205 almost 3 L/min (Table 1) did not restore  $\text{MCAV}_{\text{mean}}$  towards normothermic levels (Fig. 1). However,  
206 acute volume infusion during hyperthermia did attenuate LBNP-induced reductions in  $\text{MCAV}_{\text{mean}}$  (Fig.  
207 2). This was likely a function of the volume infusion's augmentation of cardiac output and stroke  
208 volume prior to LBNP (Fig. 3), which better maintained MAP at a given level of LBNP (Fig. 3), thereby  
209 forestalling LBNP-induced reductions in  $\text{MCAV}_{\text{mean}}$  (Fig. 2). These data indicate that cardiac output is  
210 not capable of directly (i.e., independent of arterial pressure) modulating cerebral blood flow during  
211 hyperthermia. However, the data do support that the beneficial effects of acute volume loading prior to  
212 a hyperthermic simulated hemorrhage are, at least partially, mediated via the preservation of arterial  
213 pressure and by extension, the maintenance of cerebral perfusion.

214  
215 *Acute volume expansion and cerebral perfusion during hyperthermia*

216 During normothermia, experimentally-induced fluctuations in cardiac output directly modulate  
217 brain blood flow in humans (24). Presumably, this effect is mediated via the arterial baroreflex and  
218 subsequent changes in cerebral vascular tone occurring secondary to changes in sympathetic nerve  
219 activity (22, 23). Accordingly, we hypothesized that the same phenomenon would occur during  
220 hyperthermia, such that the augmentation of cardiac output would (at least partially) restore  
221 hyperthermia-induced reductions in cerebral perfusion. However, this was not the case (Fig. 1). There  
222 are two potential reasons for this observation.

223 First, acute volume expansion during hyperthermia restores central blood volume to  
224 normothermic levels (9) and augments an already elevated skin blood flow (7). Thus, increases in  
225 blood flow as a consequence of volume infusion in those vascular beds with a low vascular resistance  
226 (e.g., the cutaneous vasculature) appear likely, whereas blood flow in vascular beds with a higher  
227 vascular resistance (e.g., the cerebral vasculature) would remain constant. As evidence for this  
228 hypothesis, in the present study systemic vascular resistance further decreased during volume infusion  
229 (Table 1), while  $\text{MCAV}_{\text{mean}}$  and CVR were unchanged (Fig. 1).

230 Second, the effect of increasing cardiac output on the cerebral vasculature during normothermia  
231 may be mediated by the arterial baroreflex and subsequent changes in sympathetic nerve activity (22,

232 23). Hyperthermia impairs the responsiveness of some aspects of the baroreflex (5) and also shifts the  
233 baroreflex operating point (5, 11) in order to accommodate hyperthermia-induced hemodynamic  
234 changes (6). Thus, the sensitivity of the cerebral vasculature to modify blood flow to a given change in  
235 cardiac output may be reduced during hyperthermia. However, this remains speculative as there is no  
236 direct evidence in support of such an arrangement. It is also notable that this hypothesis requires that  
237 the sympathetic nervous system innervate cerebral vessels and modify cerebral blood flow in humans,  
238 which remains debated (28).

239

#### 240 *Acute volume expansion and cerebral perfusion during hyperthermic LBNP*

241 The ability to withstand a hemorrhagic challenge is reduced during hyperthermia, while acute  
242 volume expansion reverses this intolerance (17). The mechanisms underlying this observation are not  
243 currently known. We hypothesized that, relative to hyperthermia alone, acute volume expansion during  
244 hyperthermia would attenuate reductions in cerebral perfusion at a given level of LBNP. The present  
245 data support this hypothesis. Specifically, following volume infusion,  $MCAv_{mean}$  during LBNP was  
246 higher than during hyperthermia alone (Fig. 2). These data indicate that during simulated hemorrhage  
247 cerebral perfusion is better maintained during hyperthermia following volume expansion. From the  
248 testing of our first hypothesis, the mechanism for this observation is not via the direct influence of acute  
249 volume loading, and subsequent increases in cardiac output, on cerebral perfusion prior the simulated  
250 hemorrhagic challenge. Rather, these data support the proposal (see: 3, 10) that volume expansion  
251 results in a higher cardiac output and stroke volume at a given level of LBNP (Fig. 3), which better  
252 maintains arterial pressure (Fig. 3) and in turn maintains cerebral perfusion as LBNP progressed (Fig.  
253 2). Thus, these data suggest that the preservation of simulated hemorrhagic tolerance following  
254 volume infusion during hyperthermia is, at least partially, mediated via attenuations in LBNP-induced  
255 reductions in arterial pressure and cerebral perfusion.

256

#### 257 *Methodological considerations*

258 Given the invasive nature of this study, it was not feasible to randomize the three experimental  
259 conditions as this would have required three separate laboratory visits and thus, arterial and right heart  
260 catheterization on three occasions. Accordingly, pulmonary artery blood temperature was slightly  
261 higher ( $\sim 0.2^{\circ}\text{C}$ ) during LBNP with volume infusion relative to LBNP during hyperthermia alone. Given  
262 these slight temperature differences and that cerebral perfusion progressively decreases as internal  
263 body temperature increases - albeit at larger increments than  $0.2^{\circ}\text{C}$  (13) - these findings suggest that  
264 we likely underestimated the magnitude of the beneficial effect of acute volume expansion on changes  
265 in cerebral perfusion during LBNP.

266 Given that these data were collected concurrently with another study (3), coupled with the  
267 aforementioned challenges resulting in it not being feasible to perform the experimental sessions on  
268 three separate days, in the present study we did not measure LBNP tolerance. Thus, these data have  
269 been carefully interpreted and the conclusions drawn only pertain to situations involving the  
270 administered levels of LBNP. Therefore, cerebral vascular responses during hyperthermia following  
271 acute volume expansion at the point of LBNP intolerance remain unknown. Nevertheless, the  
272 presented data provide insights into possible mechanisms underlying the beneficial effects of acute  
273 volume expansion on LBNP tolerance during hyperthermia.

274 It is also worth noting that in the present study subjects were exposed to moderate levels of  
275 LBNP three times within a relatively short time period (~90 min). It remains unknown whether there are  
276 any physiological effects of repeated moderate LBNP over this period, and if so whether those effects  
277 would be sufficient to influence the profound changes observed during heat stress and heat stress plus  
278 volume infusion. That said, some changes do occur given that adaptation to daily LBNP exposures has  
279 been observed in as little as five consecutive days (18). Whether this influenced the conclusions drawn  
280 presently remains uncertain.

281 We utilized transcranial Doppler to quantify  $MCAv_{mean}$ , which served as an index of cerebral  
282 perfusion given that this artery supplies ~80% of the blood flow received by each cerebral hemisphere  
283 (20). However, it must be acknowledged that if the diameter of the insonated artery changes, then  
284 changes in blood velocity does not always reflect proportional changes in blood flow. Yet, the diameter  
285 of the middle cerebral artery is unaffected by moderate carbon dioxide and blood pressure  
286 perturbations (16, 26). Even still, the effect of hyperthermia on middle cerebral artery diameter remains  
287 uncertain.

288

### 289 *Conclusions*

290 The present study demonstrates that acute volume expansion does not reverse hyperthermia-  
291 induced reductions in cerebral perfusion at rest, but that it does attenuate the reduction in cerebral  
292 perfusion during a subsequent simulated hemorrhage while hyperthermic. Thus, cardiac output does  
293 not appear to directly (i.e., independent of arterial pressure) modulate cerebral blood flow during  
294 hyperthermia. However, acute volume loading prior to a simulated hemorrhagic event while  
295 hyperthermic attenuates the LBNP-induced reductions in arterial pressure and, thereby better maintains  
296 cerebral perfusion.

297

### 298 *Perspectives*

299 Testing of these hypotheses has furthered the understanding of the mechanisms by which acute  
300 volume infusion preserves the capacity to withstand a subsequent hemorrhagic challenge during

301 hyperthermia. The findings presented have implications for individuals at risk of a hemorrhagic injury  
302 under heat stress conditions (e.g., soldiers, firefighters, miners, etc.). The data suggest that plasma  
303 volume loading in a hyperthermic individual prior to a hemorrhagic injury will assist in the maintenance  
304 of cerebral perfusion through stabilizing arterial pressure, as opposed to a direct effect of an increase in  
305 cardiac output, independent of arterial pressure, as has been found in normothermic individuals (24).

306

307

308 **Acknowledgements**

309           This research was funded in part by grants from the National Heart, Lung, and Blood Institute  
310 (C.G.C.: HL-61388 and HL-67422; and Z.J.S.: T32HL007360), Aase & Ejnar Danielsens Foundation  
311 (N.H.S.) and Jeppe Juhl & Hustrus Foundation (M.B).

312

313

## 314 REFERENCES

- 315 1. **Aaslid R, Markwalder TM, and Nornes H.** Noninvasive transcranial Doppler ultrasound  
316 recording of flow velocity in basal cerebral arteries. *J Neurosurg* 57: 769-774, 1982.
- 317 2. **Brothers RM, Wingo JE, Hubing KA, and Crandall CG.** The effects of reduced end-tidal  
318 carbon dioxide tension on cerebral blood flow during heat stress. *J Physiol-London* 587: 3921-3927,  
319 2009.
- 320 3. **Bundgaard-Nielsen M, Wilson TE, Seifert T, Secher NH, and Crandall CG.** Effect of volume  
321 loading on the Frank-Starling relation during reductions in central blood volume in heat-stressed  
322 humans. *J Physiol* 588: 3333-3339, 2010.
- 323 4. **Cooke WH, Ryan KL, and Convertino VA.** Lower body negative pressure as a model to study  
324 progression to acute hemorrhagic shock in humans. *J Appl Physiol* 96: 1249-1261, 2004.
- 325 5. **Crandall CG.** Carotid baroreflex responsiveness in heat-stressed humans. *Am J Physiol Heart*  
326 *Circ Physiol* 279: H1955-1962, 2000.
- 327 6. **Crandall CG, Cui J, and Wilson TE.** Effects of heat stress on baroreflex function in humans.  
328 *Acta Physiol Scand* 177: 321-328, 2003.
- 329 7. **Crandall CG, Levine BD, and Etzel RA.** Effect of increasing central venous pressure during  
330 passive heating on skin blood flow. *J Appl Physiol* 86: 605-610, 1999.
- 331 8. **Crandall CG, Shibasaki M, and Wilson TE.** Insufficient cutaneous vasoconstriction leading up  
332 to and during syncopal symptoms in the heat stressed human. *Am J Physiol Heart Circ Physiol* 299:  
333 H1168-1173, 2010.
- 334 9. **Crandall CG, Wilson TE, Marving J, Bundgaard-Nielsen M, Seifert T, Klausen T, Andersen**  
335 **F, Secher N, and Hesse B.** Colloid volume loading does not mitigate decreases in central blood  
336 volume during simulated hemorrhage while heat stressed. *J Physiol* 590: 1287-1297, 2012.
- 337 10. **Crandall CG, Wilson TE, Marving J, Vogelsang TW, Kjaer A, Hesse B, and Secher NH.**  
338 Effects of passive heating on central blood volume and ventricular dimensions in humans. *J Physiol*  
339 586: 293-301, 2008.
- 340 11. **Cui J, Wilson TE, and Crandall CG.** Baroreflex modulation of sympathetic nerve activity to  
341 muscle in heat-stressed humans. *Am J Physiol Regul Integr Comp Physiol* 282: R252-258, 2002.
- 342 12. **Dill DB, and Costill DL.** Calculation of percentage changes in volumes of blood, plasma, and  
343 red cells in dehydration. *J Appl Physiol* 37: 247-248, 1974.
- 344 13. **Fan JL, Cotter JD, Lucas RA, Thomas K, Wilson L, and Ainslie PN.** Human  
345 cardiorespiratory and cerebrovascular function during severe passive hyperthermia: effects of mild  
346 hypohydration. *J Appl Physiol* 105: 433-445, 2008.
- 347 14. **Ganio MS, Overgaard M, Seifert T, Secher NH, Johansson P, Meyer M, and Crandall CG.**  
348 Effect of heat stress on cardiac output and systemic vascular conductance during simulated  
349 hemorrhage to pre-syncope in young men. *Am J Physiol Heart Circ Physiol* 302: H1756-H1761, 2012.
- 350 15. **Ganz W, Donoso R, Marcus HS, Forrester JS, and Swan HJ.** A new technique for  
351 measurement of cardiac output by thermodilution in man. *Am J Cardiol* 27: 392-396, 1971.
- 352 16. **Giller CA, Bowman G, Dyer H, Mootz L, and Krippner W.** Cerebral Arterial Diameters during  
353 Changes in Blood Pressure and Carbon Dioxide during Craniotomy. *Neurosurgery* 32: 737-742, 1993.
- 354 17. **Keller DM, Low DA, Wingo JE, Brothers RM, Hastings J, Davis SL, and Crandall CG.** Acute  
355 volume expansion preserves orthostatic tolerance during whole-body heat stress in humans. *J Physiol*  
356 587: 1131-1139, 2009.
- 357 18. **Lightfoot JT, Febles S, and Fortney SM.** Adaptation to repeated presyncopal lower body  
358 negative pressure exposures. *Aviat Space Environ Med* 60: 17-22, 1989.
- 359 19. **Lind AR, Leithead CS, and McNicol GW.** Cardiovascular changes during syncope induced by  
360 tilting men in the heat. *J Appl Physiol* 25: 268-276, 1968.
- 361 20. **Lindegaard KF, Lundar T, Wiberg J, Sjoberg D, Aaslid R, and Nornes H.** Variations in  
362 middle cerebral artery blood flow investigated with noninvasive transcranial blood velocity  
363 measurements. *Stroke* 18: 1025-1030, 1987.

- 364 21. **Nelson MD, Haykowsky MJ, Stickland MK, Altamirano-Diaz LA, Willie CK, Smith KJ,**  
365 **Petersen SR, and Ainslie PN.** Reductions in cerebral blood flow during passive heat stress in humans:  
366 partitioning the mechanisms. *J Physiol-London* 2011.
- 367 22. **Ogoh S, and Ainslie PN.** Cerebral blood flow during exercise: mechanisms of regulation. *J*  
368 *Appl Physiol* 107: 1370-1380, 2009.
- 369 23. **Ogoh S, and Ainslie PN.** Regulatory mechanisms of cerebral blood flow during exercise: new  
370 concepts. *Exerc Sport Sci rev* 37: 123-129, 2009.
- 371 24. **Ogoh S, Brothers RM, Barnes Q, Eubank WL, Hawkins MN, Purkayastha S, A OY, and**  
372 **Raven PB.** The effect of changes in cardiac output on middle cerebral artery mean blood velocity at  
373 rest and during exercise. *J Physiol* 569: 697-704, 2005.
- 374 25. **Pearson J, Lucas RA, and Crandall CG.** Elevated local skin temperature impairs cutaneous  
375 vasoconstrictor responses to a simulated hemorrhagic challenge while heat stressed. *Exp Physiol*  
376 2012.
- 377 26. **Serrador JM, Picot PA, Rutt BK, Shoemaker JK, and Bondar RL.** MRI Measures of Middle  
378 Cerebral Artery Diameter in Conscious Humans During Simulated Orthostasis. *Stroke* 31: 1672-1678,  
379 2000.
- 380 27. **Taylor WF, Johnson JM, Kosiba WA, and Kwan CM.** Cutaneous vascular responses to  
381 isometric handgrip exercise. *J Appl Physiol* 66: 1586-1592, 1989.
- 382 28. **van Lieshout JJ, and Secher NH.** Point:Counterpoint: Sympathetic activity does/does not  
383 influence cerebral blood flow. Point: Sympathetic activity does influence cerebral blood flow. *J Appl*  
384 *Physiol* 105: 1364-1366, 2008.
- 385 29. **Willie CK, Colino FL, Bailey DM, Tzeng YC, Binsted G, Jones LW, Haykowsky MJ,**  
386 **Bellapart J, Ogoh S, Smith KJ, Smirl JD, Day TA, Lucas SJ, Eller LK, and Ainslie PN.** Utility of  
387 transcranial Doppler ultrasound for the integrative assessment of cerebrovascular function. *J Neurosci*  
388 *Methods* 196: 221-237, 2011.
- 389 30. **Wilson TE, Cui J, Zhang R, and Crandall CG.** Heat stress reduces cerebral blood velocity and  
390 markedly impairs orthostatic tolerance in humans. *American Journal of Physiology: Regulatory,*  
391 *Integrative and Comparative Physiology* 291: R1443-1448, 2006.
- 392 31. **Wilson TE, Cui J, Zhang R, Witkowski S, and Crandall CG.** Skin cooling maintains cerebral  
393 blood flow velocity and orthostatic tolerance during tilting in heated humans. *J Appl Physiol* 93: 85-91,  
394 2002.
- 395 32. **Wilson TE, Tollund C, Yoshiga CC, Dawson EA, Nissen P, Secher NH, and Crandall CG.**  
396 Effects of heat and cold stress on central vascular pressure relationships during orthostasis in humans.  
397 *J Physiol* 585: 279-285, 2007.

398

399

400

401

402 **FIGURE LEGENDS**

403

404 Figure 1: Indices of cerebral perfusion and cerebral vascular resistance during Normothermia,  
405 Hyperthermia, and during hyperthermia following acute volume infusion (Hyperthermia + Infusion)  
406 (mean  $\pm$  SD).  $MCAv_{mean}$ , mean middle cerebral artery blood velocity; CVR, cerebral vascular  
407 resistance; \*, indicates significantly different from Normothermia ( $P \leq 0.03$ ).



408

409 Figure 2: Indices of cerebral perfusion and cerebral vascular resistance at baseline and during 15 and  
410 30 mmHg lower body negative pressure (LBNP) during Hyperthermia and hyperthermia following an  
411 acute volume infusion (Hyperthermia + Infusion) (mean  $\pm$  SD).  $MCAv_{mean}$ , mean middle cerebral artery  
412 blood velocity; CVR, cerebral vascular resistance;  $\Delta$ , indicates change from pre-LBNP baseline for each  
413 condition; †, indicates significantly different from Hyperthermia ( $P < 0.05$ ).



414


415 Figure 3: Hemodynamic variables at baseline and during 15 and 30 mmHg lower body negative  
416 pressure (LBNP) during Hyperthermia and hyperthermia following an acute volume infusion  
417 (Hyperthermia + Infusion) (mean  $\pm$  SD). MAP, mean arterial pressure; CVP: central venous pressure;  
418 SVR, systemic vascular resistance;  $\Delta$ , indicates change from pre-LBNP baseline for each condition; †,  
419 indicates significantly different from Hyperthermia ( $P \leq 0.011$ ).

420



- Normothermia
- Hyperthermia
- Hyperthermia + Infusion





**Table 1: Baseline thermal and hemodynamic data (mean  $\pm$  SD)**

|  | Normothermia   | Hyperthermia     | Hyperthermia + Infusion |
|--|----------------|------------------|-------------------------|
| Pulmonary artery blood temperature ( $^{\circ}$ C) | 36.6 $\pm$ 0.2 | 37.7 $\pm$ 0.4 * | 37.9 $\pm$ 0.3 *        |
| Mean skin temperature ( $^{\circ}$ C)              | 34.9 $\pm$ 0.2 | 37.7 $\pm$ 0.4 * | 37.7 $\pm$ 0.4 *        |
| Cardiac output (L/min)                             | 6.4 $\pm$ 0.8  | 10.9 $\pm$ 2.0 * | 13.8 $\pm$ 2.4 *†       |
| Heart rate (bpm)                                   | 61 $\pm$ 11    | 90 $\pm$ 14 *    | 98 $\pm$ 11 *†          |
| Stroke volume (ml)                                 | 108 $\pm$ 19   | 123 $\pm$ 28     | 143 $\pm$ 29 *          |
| MAP (mmHg)   | 89 $\pm$ 8     | 79 $\pm$ 7 *     | 79 $\pm$ 6 *            |
| CVP (mmHg)   | 5.8 $\pm$ 1.5  | 3.2 $\pm$ 2.1 *  | 5.1 $\pm$ 2.5 †         |
| SVR (mmHg/L/min)                                   | 13.2 $\pm$ 2.3 | 7.2 $\pm$ 1.5 *  | 5.5 $\pm$ 1.0 *†        |
| P <sub>a</sub> CO <sub>2</sub> (mmHg)              | 39 $\pm$ 2     | 39 $\pm$ 4       | 37 $\pm$ 6              |

MAP, mean arterial blood pressure; CVP, central venous pressure; SVR, systemic vascular resistance; P<sub>a</sub>CO<sub>2</sub>, arterial carbon dioxide tension; \* indicates significantly different than normothermia (P $\leq$ 0.01); † indicates significantly different than hyperthermia (P<0.05).